Mascoma Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Mascoma Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18K	Hold	40	–	–	﹤0.01%	447
2026 Q1	$1.9K	Hold	40	–	–	﹤0.01%	430
2025 Q4	$2.1K	Hold	40	–	–	﹤0.01%	412
2025 Q3	$2.59K	Hold	40	–	–	﹤0.01%	413
2025 Q2	$1.95K	Hold	40	–	–	﹤0.01%	439
2025 Q1	$1.36K	Buy	+40	New	+$1.7K	﹤0.01%	469
2024 Q3	–	Sell	-41	Closed	-$2.21K	–	468
2024 Q2	$2.21K	Hold	41	–	–	﹤0.01%	459
2024 Q1	$2.79K	Hold	41	–	–	﹤0.01%	419
2023 Q4	$2.57K	Hold	41	–	–	﹤0.01%	435
2023 Q3	$1.86K	Hold	41	–	–	﹤0.01%	467
2023 Q2	$2.17K	Sell	41 -250	-86%	-$14.2K	﹤0.01%	444
2023 Q1	$14.2K	Hold	291	–	–	﹤0.01%	369
2022 Q4	$11.8K	Buy	291 +41	+16%	+$2.17K	﹤0.01%	389
2022 Q3	$16K	Hold	250	–	–	0.01%	350
2022 Q2	$15K	Hold	250	–	–	0.01%	373
2022 Q1	$16K	Buy	+250	New	+$15.7K	0.01%	391

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mascoma Wealth Management's CRSP Position: Q2 2026 in Review

Mascoma Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 40 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #447.

Mascoma Wealth Management first reported a position in CRSP in Q1 2022 and has held it in 16 quarters since. The position peaked at $16K in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Mascoma Wealth Management held 40 shares of CRISPR Therapeutics worth $2.18K as of Q2 2026.
Mascoma Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Mascoma Wealth Management's portfolio in Q2 2026, its #447 holding.
Mascoma Wealth Management first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 16 quarters since.
Mascoma Wealth Management's CRISPR Therapeutics position peaked at $16K in Q3 2022.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mascoma Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.